H. Janssen, P. Lampertico, Chien-Hung Chen, J. Heo, C. Fournier, S. Ahn, Tak Yin Owen Tsang, C. Coffin, Yi-Hsang Huang, G. Marchesini, A. Hui, M. Elkhashab, Sayed Jafri, Carol Yee Kwan Chan, Susanna K. Tan, Yang Zhao, V. Suri, J. Flaherty, A. Gaggar, D. Brainard, W. Chuang, K. Agarwal, E. Gane, Y. Lim
{"title":"中度或重度肾功能损害或终末期肾病(ESRD)的病毒抑制型慢性乙型肝炎(CHB)患者从富马酸替诺福韦二氧丙酯(TDF)和/或其他口服抗病毒药物(OAVS)切换到替诺福韦α胺(TAF)","authors":"H. Janssen, P. Lampertico, Chien-Hung Chen, J. Heo, C. Fournier, S. Ahn, Tak Yin Owen Tsang, C. Coffin, Yi-Hsang Huang, G. Marchesini, A. Hui, M. Elkhashab, Sayed Jafri, Carol Yee Kwan Chan, Susanna K. Tan, Yang Zhao, V. Suri, J. Flaherty, A. Gaggar, D. Brainard, W. Chuang, K. Agarwal, E. Gane, Y. Lim","doi":"10.1136/gutjnl-2021-iddf.80","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":9921,"journal":{"name":"Chinese Journal of Clinical Hepatology","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2021-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"IDDF2021-ABS-0078 Switching from tenofovir disoproxil fumarate (TDF) and/or other oral antivirals (OAVS) to tenofovir alafenamide (TAF) in virally suppressed chronic hepatitis B (CHB) patients with moderate or severe renal impairment, or with end-stage renal disease (ESRD)\",\"authors\":\"H. Janssen, P. Lampertico, Chien-Hung Chen, J. Heo, C. Fournier, S. Ahn, Tak Yin Owen Tsang, C. Coffin, Yi-Hsang Huang, G. Marchesini, A. Hui, M. Elkhashab, Sayed Jafri, Carol Yee Kwan Chan, Susanna K. Tan, Yang Zhao, V. Suri, J. Flaherty, A. Gaggar, D. Brainard, W. Chuang, K. Agarwal, E. Gane, Y. Lim\",\"doi\":\"10.1136/gutjnl-2021-iddf.80\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":9921,\"journal\":{\"name\":\"Chinese Journal of Clinical Hepatology\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2021-09-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Chinese Journal of Clinical Hepatology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1136/gutjnl-2021-iddf.80\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Chinese Journal of Clinical Hepatology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1136/gutjnl-2021-iddf.80","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
IDDF2021-ABS-0078 Switching from tenofovir disoproxil fumarate (TDF) and/or other oral antivirals (OAVS) to tenofovir alafenamide (TAF) in virally suppressed chronic hepatitis B (CHB) patients with moderate or severe renal impairment, or with end-stage renal disease (ESRD)